Company:  SESEN BIO, INC. (SESN)
Form Type:  S-8
Filing Date:  11/14/2019 
CIK:  0001485003 
Address:  245 FIRST STREET
SUITE 1800
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-444-8550 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.57  
Change: 
-0.0493 (-8.02%)  
Trade Time: 
Mar 27  
Market Cap: 
$62.25M
Trade SESN now with 

© 2020  
Description of Business
We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody.
Register and access this filing in:     
  FORM S-8
    SESEN BIO, INC. 2014 STOCK INCENTIVE PLAN
    CALCULATION OF REGISTRATION FEE
    PART I
    PART II
      Item 3. Incorporation of Documents by Reference.
    Item 5. Interests of Named Experts and Counsel.
      Item 6. Indemnification of Directors and Officers.
      Item 7. Exemption from Registration Claimed.
      Item 8. Exhibits.
      Item 9. Undertakings.
    EXHIBIT INDEX
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT 5.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 99.3